Alteon Inc. and Scios Inc. fell victim to a zero-sum heuristic at Hoechst Marion Roussel as the merged pharmaceutical company continued to set its own stamp on research priorities.

The Kansas City, Mo., pharmaceutical company ended collaborations with ALTN covering diabetes and with SCIO for Alzheimer's, the second and third projects HMR has dropped from the portfolio it inherited from the acquisition of Marion Merrell Dow. In March, HMR dropped a partnership with ImmuLogic Pharmaceutical Corp. in allergy (see BioCentury Extra, March 12).